Sleep Medication Used by 8.4% of Adults in 2020
8.4 percent of adults took sleep meds every day or most days in last 30 days; women were more likely to take sleep meds than men
Diagnosis & Disease Information
Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
ACP Updates Clinical Guidelines for Major Depressive Disorder Treatment
The updated recommendations include both nonpharmacologic and pharmacologic interventions for adults in the acute phase of MDD.
Feds to Investigate Overuse of Antipsychotic Drugs by Nursing Homes
U.S. health officials are cracking down on the inappropriate use of antipsychotic drugs to sedate patients in nursing homes
Frequent Green Space Visits Linked to Lower Use of Certain Meds
Lower use of psychotropic, antihypertensive, and asthma medications observed; association attenuated by body mass index
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Antipsychotics Increasingly Being Prescribed to Children
Period prevalence of all antipsychotic prescriptions increased 3.3 percent per year from 2000 to 2019
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Brexpiprazole Gets Priority Review for Agitation With Alzheimer Dementia
The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia.
MPR Weekly Dose Podcast #143
Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.
